TWST
Twist Bioscience Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
145.30
▲ 8.97 (6.58%)
MARKET · —
Price
Open
137.85
Prev close
136.33
Day high
145.93
Day low
135.11
Volume
1.79M
Market cap
$9.13B
P/E (TTM)
—
52W range
23.30 – 145.93
Trailing performance
Returnvs SPY
1W
+22.79%
+24.2%
1M
+57.50%
+53.8%
3M
+147.43%
+144.3%
6M
+199.63%
+188.6%
YTD
+358.98%
+346.7%
1Y
+450.43%
+430.4%
3Y
+653.96%
+579.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$9.13B
Enterprise value$9.07B
Revenue (TTM)$431.80M
Gross profit$224.38M
EBITDA$-115.28M
Net income$-136.72M
EPS (TTM)$-2.23
Free cash flow$-64.82M
Total cash$166.84M
Total debt$108.59M
Book value / share$7.11
Shares outstanding62.71M
Float61.20M
Short % of float28.74%
Dividend yield—
Beta (5Y)2.16
Valuation & profitability ratios
Trailing P/E—
Forward P/E-229.88
PEG ratio—
Price / sales—
Price / book20.47
EV / revenue21.01
EV / EBITDA-78.69
Gross margin51.96%
Operating margin-30.65%
Profit margin-31.66%
Return on equity-29.59%
Return on assets-13.09%
Debt / equity24.36
Current ratio2.67
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $376.57M | $312.97M | $245.11M | $203.56M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$77.67M | -$208.73M | -$204.62M | -$217.86M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$77.67M | -$208.73M | -$204.62M | -$217.86M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.18 | -0.56 | -212.4% |
| Mar 2026 | -0.53 | -0.60 | -12.6% |
| Dec 2025 | -0.52 | -0.50 | +3.9% |
| Sep 2025 | -0.50 | -0.45 | +10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.03 | 2 | $123.50M | +24.7% |
| Next quarter | -0.05 | 2 | $125.59M | +21.1% |
| Current year | -0.60 | 2 | $456.29M | +21.2% |
| Next year | -0.63 | 3 | $539.23M | +18.2% |
Analyst targets & ownership
Mean target$105.30
High target$120.00
Low target$36.00
Implied upside-27.53%
Analyst count10
ConsensusBUY
Strong buy / Buy2 / 7
Hold2
Sell / Strong sell0 / 0
Held by insiders1.00%
Held by institutions115.98%
Institutions holding446
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-163.66K
Net selling
Buy transactions
10
275.76K shares
Sell transactions
63
439.43K shares
Net transactions
+73
Buys less sells
Sell : buy shares
1.6 : 1
Mixed
Insider-held shares
625.82K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 12, 26 | BLAKE KATRYN SHINEMAN Director |
SELL | 2.24K | $275.25K | Direct |
| Aug 12, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 19.95K | $2.50M | Direct |
| Aug 12, 26 | LEPROUST EMILY M Chief Executive Officer |
CONVERSION | 19.95K | $531.92K | Direct |
| Aug 10, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 113.32K | $14.18M | Direct |
| Aug 10, 26 | LEPROUST EMILY M Chief Executive Officer |
CONVERSION | 113.32K | $3.02M | Direct |
| Aug 7, 26 | CHESS ROBERT BRUCE Director |
SELL | 18.42K | $2.04M | Direct |
| Aug 7, 26 | CHESS ROBERT BRUCE Director |
CONVERSION | 18.42K | $218.98K | Direct |
| Aug 5, 26 | CHO DENNIS Officer |
SELL | 14.21K | $1.56M | Direct |
| Aug 3, 26 | FINN PATRICK JOHN President |
SELL | 2.89K | $246.41K | Direct |
| Aug 3, 26 | GREEN PAULA Officer |
SELL | 1.13K | $96.67K | Direct |
| Aug 3, 26 | WERNER ROBERT F. Officer |
SELL | 167 | $14.25K | Direct |
| Aug 3, 26 | CHO DENNIS Officer |
SELL | 1.07K | $91.29K | Direct |
| Aug 3, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 5.10K | $435.22K | Direct |
| Jul 23, 26 | FINN PATRICK JOHN President |
SELL | 2.24K | $210.13K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHAN NELSON C |
Director | 33.25K | Stock Award(Grant) |
CHESS ROBERT BRUCE |
Director | 63.61K | Sale |
CHO DENNIS |
Officer | 89.87K | Sale |
CRANDELL KEITH L. |
Director | 103.62K | Stock Award(Grant) |
FINN PATRICK JOHN |
President | 269.68K | Sale |
GREEN PAULA |
Officer | 119.28K | Sale |
LAPONIS ADAM |
Chief Financial Officer | 110.28K | Sale |
LEPROUST EMILY M |
Chief Executive Officer | 818.94K | Sale |
RAGUSA ROBERT P. |
Director | 28.98K | Stock Award(Grant) |
WERNER ROBERT F. |
Officer | 46.16K | Sale |
Moving averages & technicals
SMA 10
128.19
+13.35% from price
SMA 20
113.28
+28.52% from price
SMA 50
99.96
+45.64% from price
SMA 100
79.34
+83.13% from price
SMA 200
59.29
+145.55% from price
EMA 12
125.71
+15.58% from price
EMA 26
113.80
+27.68% from price
EMA 50
101.40
+43.29% from price
RSI (14)
69.4
Neutral
MACD (12,26,9)
11.92
Hist 2.51
ATR (14)
9.86
6.77% of price
Realised vol 30D
99.8%
Annualised
Bollinger upper
149.39
20, 2σ
Bollinger lower
77.17
20, 2σ
50 / 200 cross
Golden
99.96 vs 59.29
Trend bias
Above 200
+145.55%
Risk profile
Beta vs SPY
2.67
More volatile than market
Correlation to SPY
0.46
Loosely linked
Realised vol 30D
99.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-25.5%
Peak to trough
Max drawdown 5Y
-91.5%
Peak to trough
ATR 14
9.86
6.77% of price
Beta (reported)
2.16
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.96
Put-heavy session
Put / call open interest
0.77
Positioning, not flow
Max pain
105.00
-27.9% from spot
ATM implied vol
80.8%
Nearest strike to spot
Skew (10% OTM)
+3.4%
Puts bid over calls
Call volume
77
Contracts, this expiry
Put volume
151
Contracts, this expiry
Heaviest call OI
105.00
502 contracts
Heaviest put OI
70.00
244 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires · 3d ago
Sector Update: Healthcare
MT Newswires · 3d ago
Twist Bioscience Shares Rise After Selection by Anthropic to Evaluate Protein Design Project
MT Newswires · 3d ago
‘Pharma Bro’ Martin Shkreli Slams Anthropic’s Claude Drug-Discovery Claims: ‘This Is Not Impressive Work’
Stocktwits · 3d ago
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
24/7 Wall St. · 11d ago
Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript
Motley Fool · 12d ago
Twist Bioscience (TWST) Is Up 26.3% After Capital Raise And Guidance Hike Amid Legal Settlement Talks - Has The Bull Case Changed?
Simply Wall St. · 14d ago
Revenue Growth Reinforces Twist Bioscience Corp.’s (TWST) Technology Leadership
Insider Monkey · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.